BioStem Technologies (OTCMKTS:BSEM) Trading Down 3.5% – What’s Next?

Shares of BioStem Technologies, Inc. (OTCMKTS:BSEM) fell 3.5% during trading on Friday . The company traded as low as $3.72 and last traded at $3.8960. 32,995 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 71,423 shares. The stock had previously closed at $4.0365.

Analyst Ratings Changes

A number of research firms recently commented on BSEM. Zacks Research upgraded shares of BioStem Technologies to a “hold” rating in a research note on Wednesday, March 18th. HC Wainwright began coverage on shares of BioStem Technologies in a research note on Wednesday, May 6th. They issued a “buy” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $9.00.

BioStem Technologies Price Performance

The company has a market capitalization of $69.15 million, a PE ratio of -3.50 and a beta of 0.03. The firm’s fifty day simple moving average is $4.50 and its 200 day simple moving average is $4.81.

BioStem Technologies (OTCMKTS:BSEM) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The business had revenue of $6.14 million for the quarter, compared to the consensus estimate of $5.70 million. On average, equities research analysts anticipate that BioStem Technologies, Inc. will post -1.95 EPS for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.